



Quantel Medical Launches Breakthrough SubCyclo Laser Procedure for Treatment of Glaucoma

Safe, effective, 2-minute procedure represents important advance in treatment of this progressive, sight-threatening disease

Clermont-Ferrand, France – June 26, 2017 – Quantel Medical (Quantel), a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases, today announced the launch of the SubCyclo™ laser procedure at the World Glaucoma Congress (WGC 2017) meeting being held in Helsinki, Finland, June 28 - July 1. The SubCyclo laser procedure is a safe and effective treatment for primary open-angle glaucoma and angle-closure glaucoma.

Glaucoma is a group of eye diseases that develop due to elevated intraocular pressure (IOP), which can affect the optic nerve and cause vision loss. According to the World Health Organization, glaucoma affects more than 65 million people worldwide and is the second leading cause of legal blindness. Thermal transscleral cyclophotocoagulation is an effective treatment for glaucoma that reduces production of aqueous humor in the eye's ciliary body, lowering IOP. However, because it is a destructive procedure associated with side effects and complications, it is recommended only for patients with refractory glaucoma for whom previous treatments have failed.

SubCyclo is a novel non-thermal glaucoma treatment based on the transscleral cyclophotocoagulation principle. The procedure lowers IOP by stimulating the ciliary body and the uveoscleral pathway, a route of aqueous outflow, without destructive effects. The SubCyclo probe is available on Quantel's Supra 810 laser and based on SubLiminal™ proprietary technology.

“SubCyclo preserves the structures of the ciliary body and improves the uveoscleral outflow. Because it is not destructive, it can be used earlier in the disease process for patients with open-angle and closure-angle glaucoma instead of for only refractory cases, and it is repeatable if needed,” said Dr. Nassima Benhatchi, Hôpital Saint Joseph, Paris, France. “What’s more, this is a fast, easy procedure that we can perform with local anesthesia in 2 minutes.”

“We are delighted to bring this breakthrough, non-destructive treatment to millions of glaucoma sufferers,” said Jean-Marc Gendre, CEO of Quantel Medical. “The ability

to lower IOP safely, with the added advantages of speed and ease for patients and surgeons alike, makes this a very exciting advance in treatment of glaucoma.”

Additional information on the SubCyclo procedure with 810nm Subliminal technology will be available during WGC 2017 in exhibit booth #1004.

About Quantel Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists. These products are available through direct sales operations in the U.S. and France, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid state lasers for scientific and industrial applications. For more information, please visit www.quantel-medical.com.

Company contact:

Jan-Philippe Heydel

Jan-Philippe.Heydel@quantel-medical.fr

Media contact:

Delphine Southon

Delphine.Southon@quantel-medical.fr